Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Bruce G. Raphael, MD
Advertisement
Articles by Bruce G. Raphael, MD
Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.
Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the phase II CLARITY trial in chronic lymphocytic leukemia (CLL).
Bruce G. Raphael, MD, discusses the treatment landscape of chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Dr. Raphael on the Treatment Landscape of CLLPublished: March 3rd 2020 | Updated:
Dr. Raphael on the CLARITY Trial in CLLPublished: March 10th 2020 | Updated:
Dr. Raphael on Addressing the Risk of Tumor Lysis Syndrome in CLLPublished: April 4th 2020 | Updated:
- Dr. Raphael on the Clinical Implications of the CLL14 Trial
Published: May 8th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5